Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
Por:
Navarro-Gonzalez, JF, Arenas, MD, Henriquez-Palop, F, Lloret, MJ, Molina, P, Moreno, FR, Macia-Lagier, MA, Espinel, L, Sanchez, E, Lago, M, Crespo, A, Bover, J
Publicada:
1 feb 2021
Ahead of Print:
1 feb 2021
Resumen:
Background. The efficacy and safety of sucroferric oxyhydroxide (SO) have been reported in clinical trials. However, real-life data are scarce. This study presents data on the use, efficacy and safety of SO in real clinical practice.
Methods. We performed a retrospective multicentre study, without any influence on the prescription decisions, that included 220 patients from 11 Spanish centres. Demographic, treatment, analytical and nutritional parameters and adherence, side effects and dropout rates were collected during 6 months.
Results. SO was initiated due to inadequate control of serum phosphate (P) in 70% of participants and in 24.5% to reduce the number of tablets. Monotherapy with SO increased from 44% to 74.1%, with a reduction in the average daily number of sachets/tablets from six to two. Serum P decreased by 20% (4.61.2 versus 5.8 +/- 1.3 mg/dL; P<0.001), with a significant reduction in intact parathyroid hormone levels (P<0.01). The percentage of patients with adequate serum P control at threshold levels of 5 and 4.5 mg/dL increased by 45.4% and 35.9%, respectively. Serum ferritin was not modified, while the transferrin saturation index increased significantly (P=0.04). Serum albumin and normalized protein catabolic rate, when normalized by serum P, increased, averaging 37% and 39%, respectively (P<0.001). Adherent patients increased from 28.2% to 52.7%. Adverse effects were reported by 14.1% of participants, with abandonment of treatment in 9.5%.
Conclusions. The use of SO in real-life results in better control of serum P, a reduction in the number of tablets and an improvement in therapeutic adherence. In addition, it may be beneficial with regards to secondary hyperparathyroidism and nutritional status.
Filiaciones:
Navarro-Gonzalez, JF:
Hosp Univ Nuestra Senora Candelaria, Serv Nefrol, Santa Cruz De Tenerife, Spain
Univ La Laguna, Inst Tecnol Biomed, Santa Cruz De Tenerife, Spain
Inst Salud Carlos III, Red Invest Renal REDINREN RD16 0009, Madrid, Spain
ERA EDTA Working Grp CKD MBD, Parma, Italy
Arenas, MD:
Hosp del Mar, Serv Nefrol, Barcelona, Spain
Henriquez-Palop, F:
Ctr Dialisis Avericum Norte, Las Palmas Gran Canaria, Spain
Lloret, MJ:
Fundacio Puigvert, Serv Nefrol, Barcelona, Spain
Molina, P:
Hosp Univ Dr Peset, Serv Nefrol, Valencia, Spain
Moreno, FR:
Ctr Dialisis San Luciano, Madrid, Spain
Macia-Lagier, MA:
Hosp Gen La Palma, Serv Nefrol, Santa Cruz De La Palma, Spain
Espinel, L:
Hosp Univ Getafe, Serv Nefrol, Madrid, Spain
Sanchez, E:
Hosp Univ Cabuenes, Serv Nefrol, Gijon, Spain
Lago, M:
Complejo Hosp Univ Insular, Serv Nefrol, Las Palmas Gran Canaria, Spain
Crespo, A:
Hosp Marina Baixa, Serv Nefrol, Alicante, Spain
Bover, J:
Inst Salud Carlos III, Red Invest Renal REDINREN RD16 0009, Madrid, Spain
Fundacio Puigvert, Serv Nefrol, Barcelona, Spain
gold, Green Published
|